Triamcinolone Acetonide Extended‑Release: A Review in Osteoarthritis Pain o…

Triamcinolone acetonide extended-release (ER) 32 mg (Zilretta®) is approved in the USA for the management of osteoarthritis (OA) pain of the knee and is administered as a single, 5 mL intra-articular (IA) injection. Although the therapeutic effects from IA corticosteroids are typically short-lived, triamcinolone acetonide ER is formulated in poly (lactic-co-glycolic acid) (PLGA) microsphere…

Intramuscular High-Dose Triamcinolone Acetonide in the Treatment of Severe Ch…

We describe our experience with administering intramuscular triamcinolone acetonide to 22 steroiddependent patients with asthma. These patients represent the minority of those with asthma whose disease is characterized by frequent emergency department visits, hospital admissions, and long-term dependency on oral corticosteroid therapy. The participants were randomly assigned to 2 treatment grou…

Intramuscular triamcinolone acetonide in chronic severe asthma

Seventeen subjects with chronic severe asthma completed a 48 week prospective, double blind study with crossover of treatment at 24 weeks, in which triamcinolone acetonide 80 mg intramuscularly every four weeks was compared with oral prednisolone 10 mg daily. Spirometry, twice daily measurements of peak expiratory flow rate, and self assessment of asthma symptom scores showed significant impro…

Triamcinolone in Asthma and Secondary Bronchospastic Pulmonary Emphysema

Triamcinolone possesses, in common with other clinically useful corticosteroids, the striking ability to curtail the allergic reaction irrespective of wide differences in precipitating factors and in responsiveness to other forms of therapy. Palliative effects in bronchial asthma have been induced promptly following the administration of comparatively small doses” and it is a recent observati…

High dose intramuscular triamcinolone in severe, chronic, life-threatening as…

Edition

-

ISBN/ISSN

-

Collation

-

Series Title

-

Call Number

-

GISSI-2: A factorial randomised trial of alteplase versus streptokinase and h…

A multicentre, randomised, open trial with a 2 x 2 factorial design was conducted to compare the benefits and risks of two thrombolytic agents, streptokinase (SK, 1·5 MU infused intravenously over 30-60 min) and alteplase (tPA, 100 mg infused intravenously over 3 h) in patients with acute myocardial infarction admitted to coronary care units within 6 h from onset of symptoms. The patients were…

ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activa…

41 299 patients entering 914 hospitals up to 24 h (median 4 h) after the onset of suspected acute myocardial infarction were randomised between streptokinase (SK: 1·5 MU infused over about 1 h), tissue plasminogen activator (tPA, duteplase: 0·60 MU/kg infused over about 4 h), or anisoylated plasminogen-streptokinase activator complex (APSAC, anistreplase: 30 U over about 3 min).

ESC Guidelines for the management of acute myocardial infarction in patients …

Guidelines summarize and evaluate all available evidence—at the time of the writing process—on a particular issue, with the aim of assisting physicians in selecting the best management strategies for an individual patient with a given condition, taking into account the impact on outcome, as well as the risk–benefit ratio of particular diagnostic or therapeutic means

Relationship of treatment delays and mortality in patients undergoing fibrino…

Treatment delays may result in different clinical outcomes in patients with ST-segment elevation myocardial infarction (STEMI) who receive fibrinolytic therapy vs primary percutaneous coronary intervention (PCI). The aim of this analysis was to examine how treatment delays relate to 6-month mortality in reperfusion-treated patients enrolled in the Global Registry of Acute Coronary Events (GRACE)

An international randomized trial comparing four thrombolytic strategies for …

The relative efficacy of streptokinase and tissue plasminogen activator and the roles of intravenous as compared with subcutaneous heparin as adjunctive therapy in acute myocardial infarction are unresolved questions. The current trial was designed to compare new, aggressive thrombolytic strategies with standard thrombolytic regimens in the treatment of acute myocardial infarction. Our hypothes…